Mesa Laboratories (MLAB)
Supplies sterilization, biopharma, calibration, and clinical-genomics tools for regulated health markets.
Something off on this page? Send us feedback.
Sells life-science tools and quality-control solutions across sterilization and disinfection control, biopharmaceutical development, calibration, and clinical genomics. Revenue comes from consumables, instruments, software, services, and lab testing, with sterilization indicators and calibration tools forming the largest current pillars.
Designs and manufactures life-science tools and critical quality-control solutions for regulated pharmaceutical, healthcare, and medical-device customers. The operating structure spans Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics.
Sales move through direct teams in North America, Europe, and APAC plus independent distributors globally. The portfolio includes biological and chemical sterilization indicators, lab testing services, automated protein-analysis and peptide-synthesis systems, calibration and monitoring tools, and genetic-analysis products.
Most current weight sits in sterilization indicators and calibration solutions, while Clinical Genomics is exposed to China demand and trade conditions. The business depends on regulated customer workflows where product quality, suitability for use, cost effectiveness, and channel reach matter.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 14, 2026 | Wells Fargo | Reiterate | Rating: —Target: $94 | Target: $110 |
| Feb 4, 2026 | Wells Fargo | Reiterate | Rating: —Target: $83 | Target: $94 |
| Dec 15, 2025 | Wells Fargo | Reiterate | Rating: —Target: $120 | Target: $83 |
| Aug 8, 2025 | Wells Fargo | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $30.7M · Total debt $101.4M · Total assets $419.2M · Shareholders' equity $188.8M
- Revenue
- $60.1M
- Operating income
- $7.0M
- Net income
- $2.8M
HistoryDividendAnnual yield
| Institutions | ≈ 90.80% | 5.08M shares | |
|---|---|---|---|
| 161 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.90% | 162.3K shares | |
| 11 holders · as of Aug 17, 2026 | |||
| Other | ≈ 6.30% | 352.3K shares | |
| remainder | |||
5.60M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Conestoga Capital AdvisorsInstitution | 11.05% | 618,111 | filed Jan 10, 2025 |
Long Path Partners LPInstitution | 8.53% | 477,126 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.87% | 440,552 | as of Jun 30, 2026 |
Long Path Smaller Companies Fund, LPInstitution | 7.25% | 405,583 | filed Apr 15, 2026 |
Boston PartnersInstitution | 4.74% | 265,149 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | John James Sullivan | director | −7,093 | $112.80 |
| Aug 13, 2026 | Siddhartha Kadia | officer: President and CEO | +7,093 | $112.80 |
| Aug 13, 2026 | R. Tony Tripeny | director | +900 | $113.69 |
| Jun 22, 2026 | John Sakys | officer: CFO | −2,827 | $89.50 |
| Jun 22, 2026 | Brian David Archbold | officer: SVP Operations | −2,516 | $89.50 |
- STERIS
Sterilization-assurance rival with biological indicators and services
- Solventum
Attest sterilization monitoring competes with SDC indicator lines
- Fortive
Calibration and process-test rival through Fluke Calibration
- Thermo Fisher Scientific
Broad life-science tools rival in protein biology and genetic analysis
- Danaher
Life-science and diagnostics platform competing across BPD and genomics
- Bio-Rad Laboratories
Protein-analysis and digital-PCR rival for research and biopharma labs
- QIAGEN
Molecular testing and genomic-profiling rival to Clinical Genomics
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mesa Laboratories | $134.63 | −0.01% | $737.9M | 157.0 | 16.3 | 3.0 | +1.0% |
| STERIS | $208.79 | +0.02% | $20.17B | 25.3 | 18.2 | 3.3 | +7.1% |
| Solventum | $88.75 | −0.04% | $15.38B | 10.8 | 13.1 | 1.9 | +2.2% |
| Fortive | $55.95 | 0.00% | $16.64B | 32.4 | 17.9 | 3.9 | −27.8% |
| Thermo Fisher Scientific | $658.52 | −0.03% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Danaher | $220.87 | −0.11% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| Bio-Rad Laboratories | $379.57 | −0.01% | $10.16B | 45.7 | 36.8 | 3.9 | −0.1% |
| QIAGEN | $43.69 | 0.00% | $9.24B | 23.0 | 17.5 | 4.4 | +0.3% |
| Median | 32.4 | 18.2 | 3.9 | +2.2% |